Cargando…
National cancer database analysis of outcomes in pediatric glioblastoma
Glioblastoma in children is an aggressive disease with no defined standard therapy. We evaluated hospital‐based demographic and survival patterns obtained through the National Cancer Database to better characterize children with glioblastoma. Our study identified 1173 patients from 0 to 19 years of...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5911617/ https://www.ncbi.nlm.nih.gov/pubmed/29532996 http://dx.doi.org/10.1002/cam4.1404 |
_version_ | 1783316243385679872 |
---|---|
author | Liu, Meng Thakkar, Jigisha P. Garcia, Catherine R. Dolecek, Therese A. Wagner, Lars M. Dressler, Emily Van Meter Villano, John L. |
author_facet | Liu, Meng Thakkar, Jigisha P. Garcia, Catherine R. Dolecek, Therese A. Wagner, Lars M. Dressler, Emily Van Meter Villano, John L. |
author_sort | Liu, Meng |
collection | PubMed |
description | Glioblastoma in children is an aggressive disease with no defined standard therapy. We evaluated hospital‐based demographic and survival patterns obtained through the National Cancer Database to better characterize children with glioblastoma. Our study identified 1173 patients from 0 to 19 years of age between 1998 and 2011. Comparisons were made among demographics, clinical characteristics, treatment, and survival variables. Fifty‐four percent of patients were over 10 years of age. Approximately 80% of patients underwent either partial or complete resection. Adjuvant therapy was used variably, and its use increased with patient age. Forty‐eight percent of patients received the combination of surgery, radiation, and chemotherapy, and 4% did not receive any treatment. As expected, patients ≤5 years of age had better 5‐year survival than those ages 6–10 (P = 0.01) or 11–19 years (P = 0.0077). Other factors associated with poor survival included black race and central tumor location. Better outcomes were associated with treatment that included surgery, radiotherapy, and chemotherapy compared to any other treatment combinations. Radiotherapy had no impact on survival in the 0 to 10‐year‐old age group, but was associated with improved survival for patients 11–19 years. We report an extensive demographic and survival analysis of pediatric glioblastoma. The observed differences likely reflect variances in tumor biology and likelihood of treatment receipt. Improved survival was associated with the use of surgery, radiotherapy, and chemotherapy. Radiation therapy was not associated with survival in patients younger than 10 years of age. |
format | Online Article Text |
id | pubmed-5911617 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-59116172018-04-30 National cancer database analysis of outcomes in pediatric glioblastoma Liu, Meng Thakkar, Jigisha P. Garcia, Catherine R. Dolecek, Therese A. Wagner, Lars M. Dressler, Emily Van Meter Villano, John L. Cancer Med Clinical Cancer Research Glioblastoma in children is an aggressive disease with no defined standard therapy. We evaluated hospital‐based demographic and survival patterns obtained through the National Cancer Database to better characterize children with glioblastoma. Our study identified 1173 patients from 0 to 19 years of age between 1998 and 2011. Comparisons were made among demographics, clinical characteristics, treatment, and survival variables. Fifty‐four percent of patients were over 10 years of age. Approximately 80% of patients underwent either partial or complete resection. Adjuvant therapy was used variably, and its use increased with patient age. Forty‐eight percent of patients received the combination of surgery, radiation, and chemotherapy, and 4% did not receive any treatment. As expected, patients ≤5 years of age had better 5‐year survival than those ages 6–10 (P = 0.01) or 11–19 years (P = 0.0077). Other factors associated with poor survival included black race and central tumor location. Better outcomes were associated with treatment that included surgery, radiotherapy, and chemotherapy compared to any other treatment combinations. Radiotherapy had no impact on survival in the 0 to 10‐year‐old age group, but was associated with improved survival for patients 11–19 years. We report an extensive demographic and survival analysis of pediatric glioblastoma. The observed differences likely reflect variances in tumor biology and likelihood of treatment receipt. Improved survival was associated with the use of surgery, radiotherapy, and chemotherapy. Radiation therapy was not associated with survival in patients younger than 10 years of age. John Wiley and Sons Inc. 2018-03-13 /pmc/articles/PMC5911617/ /pubmed/29532996 http://dx.doi.org/10.1002/cam4.1404 Text en © 2018 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Cancer Research Liu, Meng Thakkar, Jigisha P. Garcia, Catherine R. Dolecek, Therese A. Wagner, Lars M. Dressler, Emily Van Meter Villano, John L. National cancer database analysis of outcomes in pediatric glioblastoma |
title | National cancer database analysis of outcomes in pediatric glioblastoma |
title_full | National cancer database analysis of outcomes in pediatric glioblastoma |
title_fullStr | National cancer database analysis of outcomes in pediatric glioblastoma |
title_full_unstemmed | National cancer database analysis of outcomes in pediatric glioblastoma |
title_short | National cancer database analysis of outcomes in pediatric glioblastoma |
title_sort | national cancer database analysis of outcomes in pediatric glioblastoma |
topic | Clinical Cancer Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5911617/ https://www.ncbi.nlm.nih.gov/pubmed/29532996 http://dx.doi.org/10.1002/cam4.1404 |
work_keys_str_mv | AT liumeng nationalcancerdatabaseanalysisofoutcomesinpediatricglioblastoma AT thakkarjigishap nationalcancerdatabaseanalysisofoutcomesinpediatricglioblastoma AT garciacatheriner nationalcancerdatabaseanalysisofoutcomesinpediatricglioblastoma AT dolecektheresea nationalcancerdatabaseanalysisofoutcomesinpediatricglioblastoma AT wagnerlarsm nationalcancerdatabaseanalysisofoutcomesinpediatricglioblastoma AT dressleremilyvanmeter nationalcancerdatabaseanalysisofoutcomesinpediatricglioblastoma AT villanojohnl nationalcancerdatabaseanalysisofoutcomesinpediatricglioblastoma |